Bioptic

Bioptic Intangible Assets

The Intangible Assets of Bioptic (6850.TWO) as of Oct 23, 2026 is 42.92 M TWD. In the previous year, Intangible Assets was 44.57 M TWD — a change of -3.71% (lower).

Intangible Assets

42.92 MTWD

YoY

-3.71%

Last updated:

Intangible Assets of Bioptic is 2024 42.92 M TWD. Intangible Assets of Bioptic was 2023 44.57 M TWD. It decreases by -3.71% lower compared to the previous year.

The Bioptic Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2018
263,000.00 TWD
Jan 1, 2019
258,000.00 TWD
Jan 1, 2020
144,000.00 TWD
Jan 1, 2021
1.36 M TWD
Jan 1, 2022
1.08 M TWD
Jan 1, 2023
44.57 M TWD
Jan 1, 2024
42.92 M TWD
The Bioptic Intangible Assets history
YEARIntangible AssetsYoY
42.92 MTWD-3.71%
44.57 MTWD+4,011.99%
1.08 MTWD-20.35%
1.36 MTWD+845.14%
144,000.00TWD-44.19%
258,000.00TWD-1.90%
263,000.00TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioptic Stock analysis

What does Bioptic do? BiOptic Inc generates revenue through the sale of capillary electrophoresis instruments, including the Qsep100, Qsep1, and Qsep400 series, which are used for biomolecule separation and detection. The company also sells related consumables such as S1, S2, S3, F3 cassettes for DNA fragment analysis, R1 and NR1 cassettes for RNA detection, P2 cassettes for protein analysis, and Q series for quantitative detection. Additionally, BiOptic Inc offers reagents including polymerase chain reaction reagents, veterinary medicine-related reagents, human gene detection reagents, and food-related reagents. These products are primarily sold to customers in China, Hong Kong, and Taiwan, with the company focusing on the healthcare and research sectors. The firm's main customer segments include laboratories, hospitals, and research institutions that require advanced detection equipment and consumables for genetic and molecular analysis. BiOptic Inc's product portfolio targets both human and veterinary medical applications, as well as food safety testing, indicating a diversified market approach. The company's focus on high-precision instruments and specialized reagents positions it to serve clients needing reliable solutions for nucleic acid and protein analysis. BiOptic Inc's revenue streams are derived from direct sales of its instruments, cassettes, and reagents to end-users in the healthcare and research sectors. The company's products are designed for specific applications, such as DNA, RNA, and protein detection, which drives demand from specialized laboratories and medical facilities. By offering a comprehensive range of products, BiOptic Inc ensures that its customers can access all necessary tools for their molecular analysis needs within a single supplier. Bioptic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioptic stock

Intangible Assets of Bioptic is 42.92 M TWD in 2024.

Intangible Assets of Bioptic changed from 44.57 M TWD to 42.92 M TWD, representing a -3.71% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Bioptic since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Bioptic historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioptic

All Key Metrics — Bioptic